<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03871309</url>
  </required_header>
  <id_info>
    <org_study_id>005-035-006-ANTR-0607</org_study_id>
    <nct_id>NCT03871309</nct_id>
  </id_info>
  <brief_title>Tigertriever Distal Vessels Registry</brief_title>
  <official_title>Tigertriever Distal Vessels Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rapid Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rapid Medical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A registry study to collect data on the Tigertriever device at restoring blood flow by&#xD;
      removing clots in M2 or distal vessels in patients experiencing acute ischemic stroke, during&#xD;
      commercial use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tigertriever is a CE marked mechanical revascularization device indicated to restore blood&#xD;
      flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic&#xD;
      stroke within 8 hours of symptom onset.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Percentage of participants with Symptomatic Intracranial Hemorrhage (SICH) or new infarct within 24 (±12) hours post-procedure.</measure>
    <time_frame>24 hours post procedure</time_frame>
    <description>Safety Endpoints. SICH shall be defined as Parenchymal Hematoma type 2 coupled with ≥4-point NIHSS deterioration at 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with a new occlusion.</measure>
    <time_frame>Day 0 (end of procedure)</time_frame>
    <description>Safety Endpoints.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with a TICI Score ≥IIb post procedure.</measure>
    <time_frame>Day 0 (end of procedure)</time_frame>
    <description>Effectiveness Endpoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with a TICI Score ≥IIb post procedure after first pass.</measure>
    <time_frame>Day 0 (end of procedure)</time_frame>
    <description>Effectiveness Endpoints</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Tigertriever</arm_group_label>
    <description>Male or female patients (age ≥18) who present with an acute ischemic stroke due to a M2 or distal (medium to small) vessel occlusion confirmed by vessel imaging and treated with the Tigertriever 17 or 13 revascularization devices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tigertriever</intervention_name>
    <description>Mechanical Thrombectomy</description>
    <arm_group_label>Tigertriever</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female patients (age ≥18) who present with an acute ischemic stroke due to a M2 or&#xD;
        distal (medium to small) vessel occlusion confirmed by vessel imaging and treated with the&#xD;
        Tigertriever 17 or 13 revascularization devices.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who present with acute ischemic stroke, who can be treated within 6 hours of&#xD;
             symptoms onset, who are either refractory to or ineligible for IV t-PA treatment and&#xD;
             intend to be treated with thrombectomy.&#xD;
&#xD;
          -  Patients ≥18&#xD;
&#xD;
          -  NIHSS Score of ≥2&#xD;
&#xD;
          -  Angiographically confirmed occlusion in a M2 or distal (medium to small) branch that&#xD;
             is accessible to the Tigertriever device (17 or 13) as determined by the vessel&#xD;
             diameter (≥1mm).&#xD;
&#xD;
          -  Anticipated life expectancy of at least 6 months from presentation&#xD;
&#xD;
          -  Signed informed consent form by the patient or a legally acceptable representative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Extended infarct - ischemic changes &gt;1/3 MCA territory / 100 ml tissue or ASPECT score&#xD;
             &lt;5&#xD;
&#xD;
               -  Pre- stroke mRS ≥ 2&#xD;
&#xD;
               -  Unknown time of stroke symptom onset&#xD;
&#xD;
               -  Vessel diameter &lt; 1mm&#xD;
&#xD;
               -  Angiographically evident extreme vessel tortuosity that may preclude the device&#xD;
                  from reaching the target area.&#xD;
&#xD;
               -  Occlusion/stenosis proximal to thrombus that precludes safe retrieval&#xD;
&#xD;
               -  Medical co-morbidities including but not limited to:&#xD;
&#xD;
               -  Uncontrolled coagulopathy such as International Normalized Ratio (INR) of &gt; 3.0&#xD;
                  or platelets count &lt; 40 x109/L or APTT &gt;50 sec&#xD;
&#xD;
               -  Serious concurrent medical illness: myocardial infarction, seizures, sepsis,&#xD;
                  uncontrolled diabetes, uncontrolled hypertension, brain tumor, renal impairment&#xD;
                  (eGFR &lt;60).&#xD;
&#xD;
               -  Baseline glucose &lt; 2.7 or &gt; 22.2 mmol/L&#xD;
&#xD;
               -  Imaging features of:&#xD;
&#xD;
                    -  raised intracranial pressure or significant mass effect (for example,&#xD;
                       midline shift, severe sulcal effacement, transcompartmental herniation)&#xD;
&#xD;
                    -  intracranial hemorrhage&#xD;
&#xD;
                    -  vascular malformation or aneurysm&#xD;
&#xD;
                    -  significant vascular abnormality such as carotid dissection, complete&#xD;
                       carotid occlusion or large/medium vessel vasculitis&#xD;
&#xD;
               -  Allergy/sensitivity to nickel-titanium or contrast media&#xD;
&#xD;
               -  Females who are pregnant or lactating&#xD;
&#xD;
               -  Unable to obtain informed consent from the patient or a suitable legal&#xD;
                  representative&#xD;
&#xD;
               -  Any other contraindication to thrombectomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyri Lobotesis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College Healthcare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noam Leser</last_name>
    <phone>+972 72 250 3331</phone>
    <email>noam@rapid-medical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Walid Haddad, Phd</last_name>
    <phone>+972 72 250 3331</phone>
    <email>walid@rapid-medical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imperial College Healthcare</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cardona, CRC</last_name>
    </contact>
    <investigator>
      <last_name>Kyri Lobotesis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

